Abstract：
UNASSIGNED: This study compared the clinical efficacy and safety of anti-methicillin-resistant Staphylococcus aureus (MRSA) quinolones for treating acute bacterial skin and skin structure infections (ABSSSIs).
UNASSIGNED: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant articles from inception to 21 July 2021. RCTs comparing the clinical efficacy and safety of anti-MRSA quinolones with other antibiotics for treating adult patients with ABSSSIs were included.
UNASSIGNED: Six RCTs were included. A total of 1,264 and 1,307 participants received the anti-MRSA quinolone-based study group and the control group. In the study group receiving anti-MRSA quinolone-based treatment, 935, 246, and 83 patients received delafloxacin, levonadifloxacin, and acorafloxacin, respectively. No significant difference was observed in the clinical cure rate at test of cure between the study and control groups (OR, 1.08; 95% CI, 0.91-1.29; I2 = 0%). In patients with MRSA-associated ABSSSIs, the clinical cure rate (OR, 1.09; 95% CI, 0.71-1.65; I2 = 0%) and microbiological response rate (OR, 1.24; 95% CI, 0.48-3.21; I2 = 0%) of anti-MRSA quinolones were similar to those of other antibiotics.
UNASSIGNED: The efficacy of anti-MRSA quinolone-based treatment is comparable to that of other anti-MRSA antibiotics for treating ABSSSIs.
UNASSIGNED: PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for relevant articles from inception to 21 July 2021. RCTs comparing the clinical efficacy and safety of anti-MRSA quinolones with other antibiotics for treating adult patients with ABSSSIs were included.
UNASSIGNED: Six RCTs were included. A total of 1,264 and 1,307 participants received the anti-MRSA quinolone-based study group and the control group. In the study group receiving anti-MRSA quinolone-based treatment, 935, 246, and 83 patients received delafloxacin, levonadifloxacin, and acorafloxacin, respectively. No significant difference was observed in the clinical cure rate at test of cure between the study and control groups (OR, 1.08; 95% CI, 0.91-1.29; I2 = 0%). In patients with MRSA-associated ABSSSIs, the clinical cure rate (OR, 1.09; 95% CI, 0.71-1.65; I2 = 0%) and microbiological response rate (OR, 1.24; 95% CI, 0.48-3.21; I2 = 0%) of anti-MRSA quinolones were similar to those of other antibiotics.
UNASSIGNED: The efficacy of anti-MRSA quinolone-based treatment is comparable to that of other anti-MRSA antibiotics for treating ABSSSIs.
摘要：
■本研究比较了抗耐甲氧西林金黄色葡萄球菌（MRSA）喹诺酮类药物治疗急性细菌性皮肤和皮肤结构感染（ABSSSI）的临床疗效和安全性。
■PubMed,Embase,从开始到2021年7月21日，对Cochrane中央受控试验登记册进行了相关文章的搜索。纳入了比较抗MRSA喹诺酮类药物与其他抗生素治疗成人ABSSSI患者的临床疗效和安全性的随机对照试验。
■包括六个RCT。共有1,264名和1,307名参与者接受了基于抗MRSA喹诺酮类药物的研究组和对照组。在接受抗MRSA喹诺酮类药物治疗的研究组中，935、246和83例患者接受了德拉氟沙星，左旋阿霉素，和阿科拉沙星,分别。研究组和对照组在治愈测试时的临床治愈率没有显着差异（OR，1.08；95%CI，0.91-1.29；I2=0%）。在MRSA相关ABSSSI的患者中，临床治愈率(OR，1.09；95%CI，0.71-1.65；I2=0%）和微生物反应率（OR，1.24；95％CI，0.48-3.21；I2=0％）的抗MRSA喹诺酮类药物与其他抗生素相似。
■基于抗MRSA喹诺酮治疗的疗效与其他抗MRSA抗生素治疗ABSSSI的疗效相当。
■PubMed,Embase,从开始到2021年7月21日，对Cochrane中央受控试验登记册进行了相关文章的搜索。纳入了比较抗MRSA喹诺酮类药物与其他抗生素治疗成人ABSSSI患者的临床疗效和安全性的随机对照试验。
■包括六个RCT。共有1,264名和1,307名参与者接受了基于抗MRSA喹诺酮类药物的研究组和对照组。在接受抗MRSA喹诺酮类药物治疗的研究组中，935、246和83例患者接受了德拉氟沙星，左旋阿霉素，和阿科拉沙星,分别。研究组和对照组在治愈测试时的临床治愈率没有显着差异（OR，1.08；95%CI，0.91-1.29；I2=0%）。在MRSA相关ABSSSI的患者中，临床治愈率(OR，1.09；95%CI，0.71-1.65；I2=0%）和微生物反应率（OR，1.24；95％CI，0.48-3.21；I2=0％）的抗MRSA喹诺酮类药物与其他抗生素相似。
■基于抗MRSA喹诺酮治疗的疗效与其他抗MRSA抗生素治疗ABSSSI的疗效相当。
